Showing results (31-40 of 68) with videos related to
Sort By:
Pageof 7
Anticancer Research|October 28, 2015
Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with MelanomaIvana Krajsová, Petr Arenberger, Radek Lakomý, et al.Rheumatology International|July 24, 2012
The HLA-Cw*06 allele and -1149 G/T polymorphism of extrapituitary promoter of PRL gene as a possible common genetic predisposing factors to psoriasis vulgaris and psoriatic arthritis in Czech populationAnna Cibulova, Marta Zajacova, Marketa Fojtikova, et al.International Journal of Molecular Sciences|October 12, 2018
ABD-Derived Protein Blockers of Human IL-17 Receptor A as Non-IgG Alternatives for Modulation of IL-17-Dependent Pro-Inflammatory AxisMarie Hlavničková, Milan Kuchař, Radim Osička, et al.Dermatology and Therapy|July 25, 2023
Calcipotriene and Betamethasone Dipropionate PAD-Cream Demonstrates Greater Treatment Efficacy in Patients with Moderate-to-Severe Psoriasis Compared to Topical Suspension/Gel: A Subgroup Analysis of Two Phase 3 StudiesLinda Stein Gold, Andreas Pinter, April Armstrong, et al.Journal of Medical Microbiology|May 12, 2009
Macrolide treatment failure in a case of secondary syphilis: a novel A2059G mutation in the 23S rRNA gene of Treponema pallidum subsp. pallidumPetra Matějková, Magdalena Flasarová, Hana Zákoucká, et al.International Journal of Dermatology|November 1, 2025
Super-Response to Guselkumab Treatment in Patients With Moderate-to-Severe Psoriasis: Real-World Data With Up to Five Years of Follow-Up in The Czech RepublicMartina Kojanova, Daniela Pejrilova, Jorga Fialova, et al.Dermatology and Therapy|November 30, 2023
Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech RepublicSpyridon Gkalpakiotis, Martina Kojanová, Jorga Fialová, et al.Expert Opinion on Biological Therapy|December 15, 2020
Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO studyAlan Menter, Petr Arenberger, Sigrid Balser, et al.Acta Dermatovenerologica Croatica : ADC|October 5, 2010
A survey of disease severity, quality of life, and treatment patterns of biologically naive patients with psoriasis in central and eastern EuropeTamás Palota, Jacek C Szepietowski, Jurai Pec, et al.Journal of the American Academy of Dermatology|July 14, 2025
Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 studyAndrew Blauvelt, Petr Arenberger, Maxwell B Sauder, et al.Pageof 7